Hepatitis B or C serologies consistent with past or current infections
History of hospitalization in past 12 months for diabetic ketoacidosis (DKA) or hyperosmolar hyperglycemic nonketotic syndrome (HHNS)
Subject who has a history of second primary cancer within the past 5 years, with the exception of:
Relapse of pneumocystis carinii pneumonia within the past year before enrollment
Patients may not have received cabazitaxel in the past
History of significant cerebrovascular disease in the past 6 months or ongoing event with active symptoms or sequelae
Untreated and uncontrolled second tumor in the past 2 years
Hepatic encephalopathy within past 12 months or requirement for medication to prevent or control encephalopathy
Untreated and uncontrolled second tumor in the past 2 years
Received PDT during the past 3 months
Any past or present chronic inflammatory colon and/or liver disease, past intestinal obstruction, pseudo or subocclusion or paralysis.
Diverticulitis (either active or history of) within the past 2 years; Note that diverticulosis is permitted
Has received any systemic bone-seeking radiopharmaceutical in the past
Prior radiopharmaceutical therapy (e.g. radium-223, strontium-89, samarium-153, etc.) within the past year
History of coronary or vascular stent placed within the past 3 months (may be extended to 1 year if medically indicated per physician discretion).
Hepatic encephalopathy within past 12 months or requirement for medications to prevent or control encephalopathy
Elevated urinary or plasma PBG or ALA values within the past year,
Participants have had at least 1 episode of vaso-occlusive crisis (VOC) in the past 12 months.
Patients who have failed nilotinib or not tolerated nilotinib in the past
Currently on a leukotriene inhibitor or used within the past 6 months
Needing medical attention for serious bleeding in past 4 weeks
Diverticulitis either active or history of within the past 2 years; note that diverticulosis is permitted
Patients with solid organ malignancy who have received chemotherapy within the past six months
Untreated and uncontrolled second tumor in the past 2 years
Serious or unstable disease within the past 3 months
Prior chemotherapy within the past 5 years
Prior chemotherapy within the past 5 years
Prior exposure to thiazolidinedione (TZD) therapy in the past 12 months
Prior exposure to CMC-544 within past 6 months
A prior history of Gliadel implantation in the past six months
Current or past history of cardiovascular disease (e.g.. past history of myocardial infarction, ischemic cardiomyopathy) unless cardiology consultation and clearance has been obtained for study participation
Patient with history of cardiac arrest within the past 6 months
A history of syncope with calorie restriction in the past or other medical comorbidity, which would make fasting potentially dangerous
Documented history of nephrolithiasis within the past 5 years
Patients with history of significant cerebrovascular disease in the past 6 months or ongoing event with active symptoms or sequelae are NOT eligible for the study
Contraindications to use of naltrexone (i.e., past history of opioid abuse or dependence or evidence of opioid use in the past 30 days; significant hepatocellular injury as evidenced by liver enzyme levels over 3 times normal limits).
History of chronic steroid use within the past 6 months
Patients who have received ipilimumab in the past are excluded
known or suspected past hepatitis C infection (including patients with past interferon 'curative' treatment),
Diverticulitis (either active or history of) within the past 2 years; note that diverticulosis is permitted
History of significant cerebrovascular disease in the past 6 months or ongoing event with active symptoms or sequelae
History of suicide attempt or preparation for attempt within the past 10 years
Diagnosed with cGVHD per the 2014 cGVHD NIH Consensus Criteria(Jagasia, 2015; Appendix 8) within the past 2 years prior to screening.
Any significant tobacco history within the past five years
The use of the following medications are excluded:\r\n* Insulin or sulfonylureas within the past 3 months\r\n* Thyroid medication use unless on stable doses for at least the past 3 months\r\n* Medications that are approved for weight loss (e.g., lorcaserin, phentermine, orlistat) within the past 3 months\r\n* Medications that are likely to cause weight gain or prevent weight loss (e.g., selective serotonin reuptake inhibitors [SSRI's], serotonin-norepinephrine reuptake inhibitors [SNRI's], corticosteroids, lithium, olanzapine, risperidone, clozapine, oral contraceptive pills, hormone replacement therapy) unless on stable doses for the past 3 months; \r\n* Medications that may affect adipokine or inflammatory markers (e.g., metformin, glitazones, steroids, non-steroidal anti-inflammatory drug [NSAIDS], angiotensin-converting enzyme [ACE] inhibitors, beta blockers and statins) unless on stable doses >= 3 months prior to registration (if discontinued, a washout of 2 weeks from prior use is required); NOTE: No medication should be discontinued without the medical direction and guidance of the prescribing provider
History of prior chemotherapy in the past 5 years
Diverticulitis (either active or history of) within the past 2 years; note that diverticulosis is permitted
History of significant cerebrovascular disease in the past 6 months or ongoing event with active symptoms or sequelae
Dose reductions due to neutropenia or thrombocytopenia in the past 6 months
Prior/concurrent therapy including:\r\n* Tamoxifen, raloxifene, letrozole, anastrozole, or exemestane in the past 6 months\r\n* Chemotherapy, biologic therapy (e.g., trastuzumab [Herceptin]), or breast radiotherapy to the breast currently affected by DCIS within the past 12 months\r\n* Any exogenous hormonal therapy including estrogen-, progesterone-, and/or androgen-based agents in the past 6 months\r\n* Phytoestrogens or over-the-counter (OTC) medications with estrogenic or androgenic properties in the past 6 months\r\n* Any black cohosh preparation within the past 6 months
History of significant cerebrovascular disease in the past 6 months or ongoing event with active symptoms or sequelae
Known active hyperparathyroid disease or other serious disturbance of calcium metabolism in the past 5 years
History of symptomatic genitourinary stones within the past year
History of significant cerebrovascular disease in the past 6 months or ongoing event with active symptoms or sequelae
Prior surgical endoscopic intervention within the past six months for Spigelman Stage 3 or 4 that may have been down staged to Spigelman 1 or 2.
History of significant cerebrovascular disease in the past 6 months or ongoing event with active symptoms
Patients with a serious cardiac condition within the past 6 months
History of significant cerebrovascular disease in the past 6 months or ongoing event with active symptoms or sequelae
Treatment with radiotherapy within the past 4 weeks or radiopharmaceutical therapy (strontium, samarium) within the past 8 weeks
The donor has had: (1) a trauma or surgery in the past 2 months
Use of oral bisphosphonates within the past 1 year
History of significant cerebrovascular disease in the past 6 months or ongoing event with active symptoms or sequelae
Significant circulatory disorders in the past 6 months
Stable steroid dose in past 4 weeks
History of significant cerebrovascular disease in the past 6 months or ongoing event with active symptoms or sequelae
History of ventricular tachyarrhythmia within the past 5 years
History of epistaxis requiring medical/surgical intervention (such as nasal packing) within the past 6 months
Other major cancer in the past 3 years.
Important cardiovascular events in the past 6 months.
Subjects who have experienced a serious adverse event associated with an RBCx procedure in the past.
History of second primary cancer within the past 5 years, with the exception of:
Treated and followed for at least the past 2 years in a specialized center that maintained detailed medical records, including transfusion history.
History or presence of alcoholism or drug abuse within the past 2 years
History of significant cerebrovascular disease in the past 3 months or ongoing event with active symptoms or sequelae
Patient is at increased bleeding risk due to concurrent conditions (eg, major injuries or surgery within the past 28 days prior to start of study treatment, history of CVA, transient ischemic attack, subarachnoid hemorrhage, or clinically significant hemorrhage within the past 3 months).
Prior invasive malignancy other than LACC diagnosed within the past 24 months, excluding anal intraepithelial neoplasia, non-melanoma skin carcinoma, or Kaposi’s sarcoma that has not required systemic chemotherapy within the past 24 months
Patients may not have had more than 7 days of treatment with ketoconazole by mouth in the past 6 months
Gliadel wafer or wafers implanted within the past 8 weeks
Using a consistent and daily amount of ST with specific nicotine and tobacco-specific nitrosamine (TSNA) levels for the past year;
History of prior treatment with chloroquine for malaria within past 24 months.
Patients that have undergone PDT, chemotherapy or radiation therapy within the past 6 months will not be considered for enrollment
Current or history of anorexia or bulimia in the past 5 years
Severe psychological impairment (e.g., hospitalization for depressive episode in the past 12 months)
Have completed cancer-related treatment within the past 3 years
Have not experienced a weight reduction >= 10% within past 6 months
No active cancer therapy (excluding chemoprevention) in the past three months, and no cancer therapy currently planned in the next 6 months
Treated with chemotherapy within the past 12 months
Severe psychological impairment (e.g., hospitalization for depressive episode in the past 12 months)
Patients will also be excluded if they report lower extremity (LE) surgery or injury to the LE in the past 3 months or a past medical history of primary hyperparathyroidism; or rhabdomyolysis
Chronic nausea over the past 4 weeks
Average nausea numeric rating scale >= 4/10 over past 24 hours at screening
Phase II: Not adherent to thorough SSE (i.e., did not check every area of the body at least once during the past 2 months)
PATIENTS: On scheduled haloperidol for delirium (=< 8 mg in the past 24 h)or rescue haloperidol of >= 4 mg for restlessness/agitation in the past 24 h
Subjects who have had radiation to one or both breasts in the past
Subjects with a current or past history of schizophrenia will also be excluded
Current or past (< 6 months) engagement in PCST for cancer
No active cancer therapy (excluding chemoprevention) in the past year, and no cancer therapy planned in the next 6 months
Phase II: Patients with MBC who\r\n* Have been diagnosed with leptomeningeal disease in the past eight weeks\r\n* Have diagnosed with progressive brain metastases after initial radiation therapy in the past eight weeks\r\n* Have been diagnosed brain metastases and began whole brain radiation therapy in the past eight weeks\r\n* Have an unplanned hospital admission and be discharged within the past eight weeks\r\n* Have been diagnosed with triple negative breast cancer and started second-line therapy within the past eight weeks\r\n* Have received at least three different therapy regimens within a twelve month period and began the third-line therapy regimen within the past eight weeks\r\n* Have HER2+ disease and started third-line therapy in the past eight weeks; or\r\n* Have estrogen receptor positive (ER+) disease and started third line chemotherapy in the past eight weeks\r\n* Have begun a treatment clinical trial in the past eight weeks
Finished with active cancer treatment within the past 4 years and are in the survivorship phase of care
History of incontinence defined as any pad use for urinary leakage in the past 6 months
Steroid hormone use (antiandrogen therapy [ADT]) within the past 12 months
Average dyspnea Borg Scale >= 4 of 10 with severe exertion over the past week
History of active opioid abuse within the past 12 months
Current and past history of hypertension
Adolescents and young adults who have completed cancer treatment within the past three months of all cancer types and stages will be recruited for this study
Known cardiovascular disease, uncontrolled hypertension, or new cardiac event within the past 6 months
Have not received chemotherapy in the past 2 months
Current or past (< 6 months) engagement in PCST for cancer
Patients who are not current with CRC screening, defined as not having completed a home fecal occult blood test (FOBT) within the past year; a flexible sigmoidoscopy within the past 5 years; or a colonoscopy within the past 10 years
Current suicidal ideation or suicide attempt within past 3 months
Past participation in an MBCT group
Past participation in ACT or formal mindfulness training, and
Past history of sexual abuse
Report all three symptoms as present in the past week with worst severity rating >= 3 (0-10 scale) for at least two of the three symptoms
Hospitalized for psychiatric reasons within the past 3 months
Active yoga practice within the past 6 months
On regular doses of benzodiazepine or chlorpromazine within the past 48 hours
History of active opioid abuse within the past 12 months
History of active opioid abuse within the past 12 months
Cancer patients currently receiving chemotherapy (started within the past month) and/or radiation therapy (started within the past week), or
Dyspnea with an average intensity level > 3/10 on the numeric rating scale over the past week
Patients who have taken melatonin within the past two weeks
Had sexual activity at least once in past 12 months (Randomized Trial Study only)
Participants must have been in their spousal relationship for at least the past 1 year
Tuberculosis requiring treatment within the past 3 years; all patients must have a negative quantiferon test within 4 weeks prior to starting study drug
Use of venlafaxine or hypnosis in the past 6 months
Uncontrolled hypertension (defined as 3 consecutive readings over the past year of over 160 systolic, and over 100 diastolic)
Postmenopausal as defined by 1) no menstrual period in the past 12 months; 2) no menstrual period in the past 6 months and an FSH level greater than 40; or 3) women who have had a bilateral oophorectomy
Has not had one of the following CRC tests:\r\n* Fecal occult blood test within the past year\r\n* Flexible sigmoidoscopy within the past five years or\r\n* Colonoscopy within the past ten years
Prior treatment with finasteride or dutasteride in the past 6 months
Adherent to CRCS guidelines defined as a home-based fecal occult blood test (FOBT) in the past year, a sigmoidoscopy (SIG) in the past 5 years, or a colonoscopy (COL) in the past 10 years
Was seen in the last 18 months a provider at one of the primary medical care clinics from the University of: General Internal Medicine (Lowry, Anschutz), Family Medicine (Westminster, Stapleton, Park Meadows, Boulder), or the Women's Integrated Services in Health (WISH) Clinic, and the individual’s primary medical care provider has provided approval for AHP CRC outreach to an AHP staff person, and have no record of a colonoscopy within the last 10 years, flexible sigmoidoscopy or double-contrast barium enema within the past 5 years, or fecal occult blood test (FOBT) within the past year
Patient must have completed curative chemotherapy within past 90 days at a Childrens Oncology Group (COG) institution
Prior history of documented DVT or PE in the past 3 months
Chronic, current or recent (within the past three months) use of leukotriene antagonists
WHITE, NON-HISPANIC: Participants having had a skin examination within the past year.
H/L: Participants having had a skin examination within the past year.
Subjects taking long-term systemic steroids defined as greater than 3 months in the past 12 months
PHASE I: Use of IT at least 10 times in the past year
SOCIAL MEDIA STUDY: Use of IT at least 10 times in the past year to be consistent with the proposed intervention criteria
Not have gardened in the past 2 gardening seasons
Patients with steroid refractory cGVHD cannot have history of the following therapies at any time in the post-transplant period: B-cell depleting biologic agents within the past 18 months, BTK/SYK/JAK/PI3K inhibitors within the past 2 weeks, CD19 chimeric antigen receptor (CAR) T-cell therapies at any time post-transplant
Active psychosis or poorly controlled depression in the past 6 months
Any suicide attempt or poorly controlled depression in the past 6 months
Participants must not have used any tobacco product in the past year
Received cessation treatment (including cessation counseling, NRT, bupropion, or varenicline) in past 2 months;
Participation in more than 3 research studies in the past 6 months.
Serious or unstable disease within the past 3 months
For Chantix:\r\n* Pregnant or breast feeding or planning to become pregnant in the next 6 months\r\n* Currently using nicotine replacement therapy (NRT)\r\n* History of suicide attempt in the past 12 months\r\n* History of thoughts of suicide in the past 12 months\r\n* History of thoughts of harming others in the past 12 months
Participants who have had any immunomodulatory treatment in the past 3 months will be excluded
Not have gardened in the past 2 gardening seasons
STUDY II: Smoked at least one cigarette over the past week
Smoked daily for the past one year
Prior treatment with pneumotoxic drugs within past year. If prior therapy in lifetime, then excluded if history of pulmonary toxicities from administration.
No change in menstrual patterns for the past 6 months preceding the time of registration
Prior chemotherapy or thoracic radiation within the past 5 years
Zero CPD for past 4 weeks
5 or more CPD for at least 6 out of past 12 months
Smoked regularly in the past year
Chronic, current or recent (within the past three months) use of leukotriene antagonists
Chronic, current or recent (within the past three months) use of glucocorticoids (systemic, topical and/or nasal sprays)
Mammogram receipt within the past 2 years
Patients with positive findings on prior imaging within the past 4 weeks are eligible
For electronic cigarettes (EC) users, daily EC use in the past 6 months, at least 10 sessions per day, with no TC exposure in the past 6 months
No anti-estrogen therapy for desmoid tumor within the past 6 months
Patients who have had excisional biopsy/lumpectomy of the current area of interest within the past 6 weeks
Patients who received radiation to the chest within the past 6 months
Subject has received a Feraheme® (ferumoxytol) Injection within the past 6 months.
Prior diagnosis of asthma, OR use of an inhaler in past three years to treat or prevent bronchospasm
Known active hyperparathyroid disease or other serious disturbance of calcium metabolism in the past 5 years
History of symptomatic genitourinary stones within the past year
Major changes in eating habits within the past 3 months
Chemotherapy/radiation within the past year
Patients with electronic health record (EHR)-documented colonoscopy in the past 10 years, sigmoidoscopy in the past 5 years, or fecal occult blood test (FOBT) or fecal immunochemical test (FIT) in the past 12 months will be excluded
Undergone chemotherapy or radiation therapy in the past 18 months prior to enrollment
Coughed up blood from lungs (also called hemoptysis) within the past year prior to enrollment
Patients who have already done the ESAS in the past
no recent (past 3 months) cardiovascular trauma: MI, stroke
History of parathyroid disorder or history or malignancy-associated hypercalcemia requiring therapy in the past 6 months
Cancer treatment within the past 3 weeks